473545-40-3

Basic information

• Product Name: Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-
• Synonyms: Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-;tert-butyl [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]carbamate;(R)-Tert-Butyl (1,3-Dihydroxy-3-Methylbutan-2-Yl)Carbamate;tert-butyl(R)-(1,3-dihydroxy-3-methylbutan-2-yl)carbamate;(R)-Tert-Butyl (1,3-Dihydroxy-3-Methylbutan-2-Yl)Carbamate(WXC03802)
• CAS NO: 473545-40-3
• Molecular Formula: C₁₀H₂₁NO₄
• Molecular Weight: 219.27804
• Product Categories: N-BOC
• Mol File: 473545-40-3.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-(473545-40-3)
• EPA Substance Registry System: Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-(473545-40-3)

Safety Data

• Hazardous Substances Data: 473545-40-3(Hazardous Substances Data)

Usage

Description

Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is a carbamic acid derivative with the molecular formula C6H13NO3. It has a unique 1R configuration and contains a hydroxy group and a hydroxymethyl group attached to a 2-methylpropyl moiety. This chemical compound is commonly used as a reagent and intermediate in organic synthesis and pharmaceutical manufacturing.

Uses

Used in Organic Synthesis:
Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is used as a reagent in organic synthesis for the preparation of various chemical compounds.
Used in Pharmaceutical Manufacturing:
Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is used as an intermediate in the production of pharmaceuticals, contributing to the development of new drugs.
Used in Medicinal Chemistry and Drug Development:
Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is used in the field of medicinal chemistry and drug development due to its potential applications in creating new therapeutic agents.
Used in Pharmaceutical Industry Research and Development:
Carbamic acid derivatives, including [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-, are studied for their biological activities and pharmacological properties, making them important targets for research and development in the pharmaceutical industry.

Upstream product

• 473452-22-1 methyl (S)-2-(tert-butoxycarbonylamino)-3-hydroxy-3-methylbutanoate 
• 864181-31-7 1-methyl-1-[(4R)-2-oxo-1,3-oxazolidin-4-yl]ethyl benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 116347-29-6 [(2S)-3,3-dimethyloxiran-2-yl]methanol 
• 556-82-1 3-methyl-2-buten-1-ol 
• 102507-13-1 N-(tert-butoxycarbonyl)-3-hydroxy-L-valine 
• 75-16-1 methylmagnesium bromide 
• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 
• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 
• 288159-36-4 tert-butyl (4R)-4-(1-hydroxy-1-methylethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 126181-46-2 (2R)-methyl 2-((tert-butoxycarbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)propanoate 
• 95715-86-9 (S)-2,2-dimethyl-oxazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 4-methyl ester 

Downstream Products

• 473452-26-5 (2S)-2-(N-t-butoxycarbonyl)amino-3-methyl-3-hydroxypropan-1-al 
• 269742-33-8 (2S)-2-(N-tert-Butoxycarbonyl)amino-3-methylbut-3-enoic acid 
• 102507-13-1 N-(tert-butoxycarbonyl)-3-hydroxy-L-valine 
• 1275621-77-6 methyl (S)-2-(2,4-dinitrophenylsulfonamido)-3-hydroxy-3-methylbutanoate 
• 1275621-78-7 methyl (S)-1-(2,4-dinitrophenylsulfonyl)-3,3-dimethylaziridine-2-carboxylate 
• 1275621-80-1 benzhydryl (S)-2-(tert-butoxycarbonylamino)-3-hydroxy-3-methylbutanoate 
• 1275621-81-2 (S)-1-(benzhydryloxy)-3-hydroxy-3-methyl-1-oxobutan-2-aminium chloride 
• 1275621-82-3 benzhydryl (S)-2-(2,4-dinitrophenylsulfonamido)-3-hydroxy-3-methylbutanoate 
• 1275621-83-4 benzhydryl (S)-1-(2,4-dinitrophenylsulfonyl)-3,3-dimethylaziridine-2-carboxylate 
• 1275621-84-5 benzhydryl (S)-3,3-dimethylaziridine-2-carboxylate 
• 59979-01-0 thiocillin I 
• 102507-19-7 (S)-tert-butyl 1-(benzyloxyamino)-3-hydroxy-3-methyl-1-oxobutan-2-ylcarbamate 
• 102507-25-5 (3S)-3-[(t-Butyloxycarbonyl)amino]-4,4-dimethyl-1-(phenylmethoxy)-2-azetidinone 
• 123176-14-7 C₁₆H₃₆N⁽¹⁺⁾*C₁₀H₁₇N₂O₇S^(1-) 

Relevant articles and documents

MONOBACTAM COMPOUNDS AND USE THEREFOR

Monobactam compounds and a use therefor. Specifically provided are chemical compounds represented by formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals, or prodrugs thereof, preparation methods therefor, pharmaceutical compositions containing said compounds, and a use of said compounds or compositions in treating bacterial infection. The present compounds feature excellent antibacterial activity, and have great hopes of becoming a therapeutic agent for bacterial infection.

Gold-Catalyzed Amide/Carbamate-Linked N, O-Acetal Formation with Bulky Amides and Alcohols

A gold-catalyzed N,O-acetal formation was established to construct an amide/carbamate-linked N,O-acetal substructure with bulky alcohols. The acyliminium cation species generated from o-alkynylbenzoic acid ester in the presence of a gold catalyst is highly reactive and underwent nucleophilic attack of various bulky alcohols and phenols at room temperature under neutral conditions, leading to the corresponding N,O-acetals in yields of 34-89% with good functional group tolerance.

N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.